Ivax Corporation announced that its wholly owned subsidiary, Ivax Pharmaceuticals, Inc. is distributing amoxicillin with clavulanate potassium, supplied and licensed by GlaxoSmithKline. Amoxicillin with clavulnate potassium is an oral antibacterial combination used for the treatment of respiratory, urinary and skin infections; and is the generic equivalent of Augmentin, which is marketed by GlaxoSmithKline. US sales for amoxicillin with clavulanate potassium were $1.4 billion for the twelve months ending September 30, 2003.
Ivax Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the US and internationally.